Octapharma Octagam Efficacy Claims Are Unsubstantiated, FDA Warning Letter Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Promotional materials disseminated by Octapharma at an American Academy of Allergy, Asthma & Immunology meeting also failed to reveal risks associated with use of the intravenous immune globulin.
You may also be interested in...
Octapharma IGIV Octagam Approved
Octapharma's IGIV product Octagam will be available in mid-June following FDA approval May 21
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.